Efficacy, Safety and Immunogenicity Study of Recombinant Zoster Vaccine(CHO Cell) in Adults Aged 40 Years and Older

NCT06447779 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

25000

Enrollment

INDUSTRY

Sponsor class

Conditions

Herpes Zoster

Interventions

BIOLOGICAL: Recombinant Zoster Vaccine (CHO Cell)
BIOLOGICAL: NaCl solution Placebo

Sponsor

MAXVAX Biotechnology Limited Liability Company